GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CombiGene AB (OSTO:COMBI) » Definitions » EV-to-EBITDA

CombiGene AB (OSTO:COMBI) EV-to-EBITDA : 0.65 (As of Jun. 03, 2024)


View and export this data going back to 2015. Start your Free Trial

What is CombiGene AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CombiGene AB's enterprise value is kr-21.21 Mil. CombiGene AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was kr-32.57 Mil. Therefore, CombiGene AB's EV-to-EBITDA for today is 0.65.

The historical rank and industry rank for CombiGene AB's EV-to-EBITDA or its related term are showing as below:

OSTO:COMBI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -15   Med: -1.15   Max: 3.5
Current: 0.65

During the past 8 years, the highest EV-to-EBITDA of CombiGene AB was 3.50. The lowest was -15.00. And the median was -1.15.

OSTO:COMBI's EV-to-EBITDA is ranked better than
75.72% of 449 companies
in the Biotechnology industry
Industry Median: 9.63 vs OSTO:COMBI: 0.65

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-03), CombiGene AB's stock price is kr3.49. CombiGene AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-1.780. Therefore, CombiGene AB's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


CombiGene AB EV-to-EBITDA Historical Data

The historical data trend for CombiGene AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CombiGene AB EV-to-EBITDA Chart

CombiGene AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -4.05 -4.22 3.78 -13.84 1.45

CombiGene AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.39 -0.85 -0.23 1.45 0.60

Competitive Comparison of CombiGene AB's EV-to-EBITDA

For the Biotechnology subindustry, CombiGene AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CombiGene AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CombiGene AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CombiGene AB's EV-to-EBITDA falls into.



CombiGene AB EV-to-EBITDA Calculation

CombiGene AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-21.212/-32.57
=0.65

CombiGene AB's current Enterprise Value is kr-21.21 Mil.
CombiGene AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-32.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CombiGene AB  (OSTO:COMBI) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

CombiGene AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.49/-1.780
=At Loss

CombiGene AB's share price for today is kr3.49.
CombiGene AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.780.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


CombiGene AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CombiGene AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CombiGene AB (OSTO:COMBI) Business Description

Traded in Other Exchanges
N/A
Address
Scheelevagen 2, Medicon Village, Lund, SWE, SE-223 81
CombiGene AB is a gene therapy explorer based in Sweden. The company is engaged in developing new methods for the treatment of neurological diseases and for epileptic patients who cannot be helped by available medical treatments at present. The company develops gene therapies with the ambition to offer patients affected by severe life-changing diseases opportunities for a better life.

CombiGene AB (OSTO:COMBI) Headlines

No Headlines